Farooq Ali U, Amjad Waseem, Kochar Tanureet, Adhikari Subash
Department of Cardiovascular Medicine, Charleston Area Medical Center, Charleston, South Carolina, USA.
Department of Digestive Diseases, Mercy Medical Center, Baltimore, Maryland, USA.
BMJ Case Rep. 2018 Sep 1;2018:bcr-2018-225490. doi: 10.1136/bcr-2018-225490.
Mitotane is a cytostatic antineoplastic agent that is used in the treatment of adrenocortical carcinoma and Cushing's syndrome. The commonly reported side effects associated with mitotane are anorexia, nausea, vomiting, diarrhoea, decreased memory, rash, gynaecomastia, arthralgias and leucopenia. We present a case of a 68-year-old female who developed gradual dyspnoea concurrent with the use of mitotane for the treatment of adrenocortical carcinoma. To the best of our knowledge and literate review, this is the first reported case of dyspnoea associated with the use of this medication. The purpose of this case report is to raise awareness about this uncommon adverse effect of mitotane that may have gone unrecognised on postmarketing surveillance because of under-reporting, lack of case follow-up or other comorbidities masking shortness of breath.
米托坦是一种细胞毒性抗肿瘤药物,用于治疗肾上腺皮质癌和库欣综合征。与米托坦相关的常见副作用包括厌食、恶心、呕吐、腹泻、记忆力减退、皮疹、男性乳房发育、关节痛和白细胞减少。我们报告一例68岁女性,在使用米托坦治疗肾上腺皮质癌期间逐渐出现呼吸困难。据我们所知和文献回顾,这是首例报告的与使用该药物相关的呼吸困难病例。本病例报告的目的是提高对米托坦这种罕见不良反应的认识,由于报告不足、缺乏病例随访或其他合并症掩盖了呼吸急促,这种不良反应在上市后监测中可能未被识别。